Literature DB >> 14571191

Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.

Catherine Tamalet1, Jacques Fantini, Christian Tourres, Nouara Yahi.   

Abstract

BACKGROUND: Evaluating the proportion of patients with mutated drug-resistant HIV-1 strains is a major issue of current AIDS research and therapy. According to a recent study in the United States, nearly 80% of HIV-1-infected patients have virus strains that are resistant to at least one antiretroviral drug. The aim of this study was to assess the extent of multiple drug resistance among individuals followed for HIV-1 infection in France.
METHODS: We compiled data in a relational database for 3884 reverse transcriptase (2248 patients) and 3915 protease (2194 patients) sequences of plasma samples submitted for testing between January 1997 and March 2002 at the reference HIV AIDS hospitals located in Marseille (France).
RESULTS: Genotypic resistance to at least one nucleoside reverse transcriptase inhibitor (NRTI) was present in 78.3%, resistance to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) was present in 38.9%, and resistance to at least one protease inhibitor (PI) was present in 47.0% of plasma samples. The proportion of patients carrying a virus with multiple resistance to three categories of drugs (at least one NRTI plus at least one NNRTI plus at least one PI) peaked at 25.9% in 2000 and stabilized at 25.5% in March 2002.
CONCLUSION: This study demonstrates the high prevalence of drug-resistant virus in a European cohort of patients currently under treatment for HIV-1 infection. New therapeutic strategies based on a more rational use of genotypic data should be worked out to prevent the development of resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14571191     DOI: 10.1097/01.aids.0000076341.42412.59

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

1.  In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Authors:  Z Gu; B Allard; J M de Muys; J Lippens; R F Rando; N Nguyen-Ba; C Ren; P McKenna; D L Taylor; R C Bethell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Synthesis and anti-HIV-1 screening of novel N'-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides.

Authors:  Sana Aslam; Matloob Ahmad; Muhammad Zia-Ur-Rehman; Catherine Montero; Mervi Detorio; Masood Parvez; Raymond F Schinazi
Journal:  Arch Pharm Res       Date:  2013-07-10       Impact factor: 4.946

3.  Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.

Authors:  Jong Hyun Cho; Lavanya Bondana; Mervi A Detorio; Cathy Montero; Leda C Bassit; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem       Date:  2014-10-13       Impact factor: 3.641

Review 4.  Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Authors:  Sonya J Snedecor; Lavanya Sudharshan; Katherine Nedrow; Abhijeet Bhanegaonkar; Kit N Simpson; Seema Haider; Richard Chambers; Charles Craig; Jennifer Stephens
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

5.  Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco.

Authors:  Hicham El Annaz; Patricia Recordon-Pinson; Rida Tagajdid; Toufik Doblali; Bouchra Belefquih; Siham Oumakhir; Omar Sedrati; Saad Mrani; Hervé Fleury
Journal:  AIDS Res Hum Retroviruses       Date:  2011-11-23       Impact factor: 2.205

Review 6.  Does palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence.

Authors:  R Harding; D Karus; P Easterbrook; V H Raveis; I J Higginson; K Marconi
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

7.  In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.

Authors:  Christian Callebaut; Kirsten Stray; Luong Tsai; Matt Williams; Zheng-Yu Yang; Carina Cannizzaro; Stephanie A Leavitt; Xiaohong Liu; Kelly Wang; Bernard P Murray; Andrew Mulato; Marcos Hatada; Tina Priskich; Neil Parkin; Swami Swaminathan; William Lee; Gong-Xin He; Lianhong Xu; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

8.  Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.

Authors:  Kirsten M Stray; Christian Callebaut; Bärbel Glass; Luong Tsai; Lianhong Xu; Barbara Müller; Hans-Georg Kräusslich; Tomas Cihlar
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.

Authors:  Janarthanan Narayanasamy; Manik R Pullagurla; Ashoke Sharon; Jianing Wang; Raymond F Schinazi; Chung K Chu
Journal:  Antiviral Res       Date:  2007-03-30       Impact factor: 5.970

10.  Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

Authors:  Tomas Cihlar; Adrian S Ray; Constantine G Boojamra; Lijun Zhang; Hon Hui; Genevieve Laflamme; Jennifer E Vela; Deborah Grant; James Chen; Florence Myrick; Kirsten L White; Ying Gao; Kuei-Ying Lin; Janet L Douglas; Neil T Parkin; Anne Carey; Rowchanak Pakdaman; Richard L Mackman
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.